Cargando…
Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
BACKGROUND: The emergence of olaparib, a poly (adenosine diphosphate (ADP)-ribose) polymerase (PARP) inhibitor to treat metastatic castration-resistant prostate cancer (mCRPC), created a measurable clinical question on whether the agent positively influences the treatment outcomes and acceptable saf...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681786/ https://www.ncbi.nlm.nih.gov/pubmed/38022404 http://dx.doi.org/10.14740/wjon1685 |
_version_ | 1785142623096274944 |
---|---|
author | Warli, Syah Mirsya Velaro, Adrian Joshua Firsty, Naufal Nandita Tala, Zaimah Zulkarnaini |
author_facet | Warli, Syah Mirsya Velaro, Adrian Joshua Firsty, Naufal Nandita Tala, Zaimah Zulkarnaini |
author_sort | Warli, Syah Mirsya |
collection | PubMed |
description | BACKGROUND: The emergence of olaparib, a poly (adenosine diphosphate (ADP)-ribose) polymerase (PARP) inhibitor to treat metastatic castration-resistant prostate cancer (mCRPC), created a measurable clinical question on whether the agent positively influences the treatment outcomes and acceptable safety factors. The objective was to elaborate on the efficacy and safety of olaparib-added regimens in treating mCRPC patients as compared to the established guideline. METHODS: The literature search was performed on several scientific databases, e.g., PubMed, Cochrane, and ScienceDirect, by applying the Boolean Term method. Statistical and risk of bias (RoB) analyses were calculated through RevMan 5.4.1. to investigate our outcomes, i.e., progression-free survival (PFS) and overall survival (OS) with the reported adverse effects (AEs). These outcomes were presented in hazard ratio (HR) and risk ratio (RR). RESULTS: Three trials consisting of 1,325 individuals with comparable baseline characteristics were investigated. The meta-analysis showed that introducing olaparib into the regimens significantly improved the PFS (HR 0.59 (0.48 - 0.73); P < 0.05), which disclosed even better outcomes among mutated homologous recombinant repair (HRR) and ataxia-telangiectasia mutated (ATM) gene (HR 0.43 (0.30 - 0.62); P < 0.05) in 95% confidence interval (CI). Furthermore, similar outcomes were observed in OS analysis (HR 0.81 (0.67 - 0.99); P < 0.05), despite olaparib group disclosed higher AEs rate with insignificant difference in mortality rate. CONCLUSION: The efficacy and safety of olaparib-added regimens in mCRPC patients need to be explored more extensively in trials because they are beneficial, particularly among HRR-mutated individuals. |
format | Online Article Text |
id | pubmed-10681786 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elmer Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-106817862023-10-21 Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis Warli, Syah Mirsya Velaro, Adrian Joshua Firsty, Naufal Nandita Tala, Zaimah Zulkarnaini World J Oncol Original Article BACKGROUND: The emergence of olaparib, a poly (adenosine diphosphate (ADP)-ribose) polymerase (PARP) inhibitor to treat metastatic castration-resistant prostate cancer (mCRPC), created a measurable clinical question on whether the agent positively influences the treatment outcomes and acceptable safety factors. The objective was to elaborate on the efficacy and safety of olaparib-added regimens in treating mCRPC patients as compared to the established guideline. METHODS: The literature search was performed on several scientific databases, e.g., PubMed, Cochrane, and ScienceDirect, by applying the Boolean Term method. Statistical and risk of bias (RoB) analyses were calculated through RevMan 5.4.1. to investigate our outcomes, i.e., progression-free survival (PFS) and overall survival (OS) with the reported adverse effects (AEs). These outcomes were presented in hazard ratio (HR) and risk ratio (RR). RESULTS: Three trials consisting of 1,325 individuals with comparable baseline characteristics were investigated. The meta-analysis showed that introducing olaparib into the regimens significantly improved the PFS (HR 0.59 (0.48 - 0.73); P < 0.05), which disclosed even better outcomes among mutated homologous recombinant repair (HRR) and ataxia-telangiectasia mutated (ATM) gene (HR 0.43 (0.30 - 0.62); P < 0.05) in 95% confidence interval (CI). Furthermore, similar outcomes were observed in OS analysis (HR 0.81 (0.67 - 0.99); P < 0.05), despite olaparib group disclosed higher AEs rate with insignificant difference in mortality rate. CONCLUSION: The efficacy and safety of olaparib-added regimens in mCRPC patients need to be explored more extensively in trials because they are beneficial, particularly among HRR-mutated individuals. Elmer Press 2023-12 2023-10-21 /pmc/articles/PMC10681786/ /pubmed/38022404 http://dx.doi.org/10.14740/wjon1685 Text en Copyright 2023, Warli et al. https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Warli, Syah Mirsya Velaro, Adrian Joshua Firsty, Naufal Nandita Tala, Zaimah Zulkarnaini Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis |
title | Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis |
title_full | Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis |
title_fullStr | Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis |
title_full_unstemmed | Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis |
title_short | Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis |
title_sort | addition of olaparib to the new hormonal agent regimen for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681786/ https://www.ncbi.nlm.nih.gov/pubmed/38022404 http://dx.doi.org/10.14740/wjon1685 |
work_keys_str_mv | AT warlisyahmirsya additionofolaparibtothenewhormonalagentregimenformetastaticcastrationresistantprostatecancerasystematicreviewandmetaanalysis AT velaroadrianjoshua additionofolaparibtothenewhormonalagentregimenformetastaticcastrationresistantprostatecancerasystematicreviewandmetaanalysis AT firstynaufalnandita additionofolaparibtothenewhormonalagentregimenformetastaticcastrationresistantprostatecancerasystematicreviewandmetaanalysis AT talazaimahzulkarnaini additionofolaparibtothenewhormonalagentregimenformetastaticcastrationresistantprostatecancerasystematicreviewandmetaanalysis |